PASSAMONTI, FRANCESCO
PASSAMONTI, FRANCESCO
Dipartimento di Oncologia ed Emato-Oncologia
Health Care Utilization Databases obtained from health system inform outcome for ruxolitinib treatment in patients with myelofibrosis
2026 B. Mora, M. Franchi, L. Margotto, O. Leoni, D. D'Ippoliti, E. Carloni, I. Cozzi, E. Santelli, F. Gemmi, C. Szasz, M. Maffioli, C. Gurnari, E. Attardi, D. Cattaneo, M. Bortolotti, N.S. Fracchiolla, A. Iurlo, G. Corrao, M.G. Della Porta, A.M. Vannucchi, M.T. Voso, P. Guglielmelli, F. Passamonti
Predicting the differential diagnosis of inherited versus acquired bone marrow failure syndromes: Development of simple clinical scoring systems
2026 M. Bortolotti, B. Fattizzo, S. Stella, J. Jiang, F. Versino, C. Engelbrecht, R. Trikha, J. Large, S. Gandhi, K. Snape, D. Consonni, F. Passamonti, W. Barcellini, A.G. Kulasekararaj
Molecular-Based Ecosystem to Improve Personalized Medicine in Chronic Myelomonocytic Leukemia
2026 L. Lanino, A.M. Hunter, N. Gagelmann, M. Robin, D. Dall'Olio, A. Flamigni, C. Sala, C. Gurnari, Y. Wang, L. Pleyer, B. Xicoy, G. Montalban-Bravo, L. Shih, A. Alsugair, S. Fathima, C. Gregorio, C. Rollo, L. Palomo, A.S. Platzbecker, G. Asti, R. Itzykson, D.A. Sallman, P. Fariselli, W. Kern, G. Garcia-Manero, U. Platzbecker, F. Solé, M. Diez-Campelo, J. Maciejewski, R. Bejar, F. Thol, N. Kroger, M. Savona, P. Fenaux, G. Sanz, S. Kordasti, V. Santini, M. Fontenay, A.M. Zeidan, R.S. Komrokji, T. Haferlach, U. Germing, G. Castellani, S. D'Amico, M. Patnaik, F. Ieva, E. Solary, A. Tefferi, E. Padron, M.G. Della Porta, N. Null, T. Haque, O. Abdel-Wahab, K. Geissler, A. Bataller, A. Bazinet, M. Meggendorfer, M. Quintavalla, A. Bruseghini, E. Sauta, L. Carota, T. Sanavia, L. Dall'Olio, E. Travaglino, L. Zamora, D. Quintela, A. Jerez, E. Cornejo, P. Garcia Martin, M. Diaz-Beya, A. Avendano Pita, V. Roldan, D.V. Fiallo Suárez, E. Cerezo Velasco, M. Calabuig, E. Such, C. Castilla-Llorente, C.E. Bulabois, L. Souchet, H. Awada, M. Bernardi, P. Chiusolo, A. Curti, L. Giaccone, C. Finelli, I. Casetti, F. Onida, L.M. Borin, M. Yung Follo, A. Consagra, F. Passamonti, E. Diral, V. Vucinic, G.M. Bergonzi, M.T. Voso, H. Hou, W. Chou, C. Yao, C. Lin, H. Tien, A. Campagna, M. Ubezio, A. Russo, G. Todisco, G. Maggioni, C.A. Tentori, A. Buizza, I. Ferrari, M. Di Matteo, A. Crespi, G. Figini, C. Delponte, F. Pesce, M. Zampini, E. Riva, M. Delleani, E. Iascone, L. Crisafulli, F. Ficara, D. Ventura, N. Pinocchio, M. Brindisi, A. Santoro, A. Kiwan, J. Vanoudenhove, N.H. Al Ali, T.A. Graubert, S. Thota, E. Griffiths
Genomic profiling for decision-making in post-polycythemia vera and post-essential thrombocythemia myelofibrosis
2026 B. Mora, F. Palandri, P. Guglielmelli, A.T. Kuykendall, M. Maffioli, A. Iurlo, V. De Stefano, S. Salmoiraghi, T. Devos, F. Itri, F. Cervantes, J. Kiladjian, M.G. Della Porta, F. Albano, J. Gotlib, G. Benevolo, M. Caramella, M. Ruggeri, E. Rumi, D.M. Ross, C. Pessina, I. Colugnat, F. Orsini, G. Micucci, G. Rotunno, R.S. Komrokji, D. Cattaneo, P. Chiusolo, M. Bortolotti, T. Barbui, D. Cilloni, M. Breccia, G.A. Palumbo, F. Branzanti, L. Margotto, M. Franchi, A.M. Vannucchi, F. Passamonti
Direct-Acting Antiviral Agents in Hepatitis C–Associated Indolent Lymphomas
2026 M. Merli, E. Genuardi, S. Zibellini, S. Rattotti, M. Spina, G. Roti, M. Motta, F. Piazza, C. Boccomini, A.J.M. Ferreri, O. Perbellini, M. Brociner, A. Dodero, D. Vallisa, A. Pulsoni, A. Santoro, I. Del Giudice, V. Zuccaro, E. Chimienti, S. Russo, C. Varraso, E. Rizzo, A. Bosi, E. Cappello, G. Favrin, L. Marcheselli, C. Visco, S. Luminari, F. Passamonti, S. Ferrero, L. Arcaini
Danazol treatment for poor graft function after hematopoietic stem cell transplantation: a single centre experience
2026 F. Serpenti, N. Galli, F. Cavallaro, K. Barbullushi, N. Cecchi, M. Goldaniga, F. Passamonti, G. Saporiti
Safety and Effectiveness of Sutimlimab in Cold Agglutinin Disease: A Real‐World International Experience
2026 B. Fattizzo, E. Sambruna, Y. Miyakawa, M. Michel, C. Visco, M. Fillitz, G. Kannourakis, M.B. Greve, M. Kleemiss, J. Cid, A. Patriarca, L. Pavan, A. Dizdari, N. Maschio, A. Sau, C. Bitetti, R.M. Colombo, L. Curreli, D. Lame, U. Markovic, F. Pappagallo, G.L. Pedone, D. Rapezzi, V. Sammartano, N. Tumedei, A.G. Solimando, J. Marit, L. Fianchi, J. Khwaja, A. De Vivo, F. Lanza, F. Vianello, E.N. Oliva, C. Broome, F. Passamonti, U. Jaeger, B. Jilma, G. Moulis, W. Barcellini
Clinical Outcomes of Ruxolitinib Treatment in Patients With IPSS Intermediate‐1‐Risk Myelofibrosis: Interim Analysis From an Italian, Prospective Study (ROMEI)
2026 P. Guglielmelli, M. Breccia, F. Mendicino, M. Martelli, N. Di Renzo, G.A. Palumbo, M. Crugnola, M. Musso, S. Sibilla, P. Sportoletti, E. Abruzzese, S. Impera, A. Malato, S. Siragusa, C. Selleri, F. Pane, B. Martino, A. Ricco, A. Gardellini, A.M. Liberati, A. Tafuri, M. Langella, M. Brociner, P. Ditonno, D. Pastore, O. Mulas, B. Pocali, M. De Gobbi, E. Morsia, G. Benevolo, E.M. Elli, V. De Stefano, A.P. Falcone, D. Vallisa, S. Tomassetti, F. Lunghi, N. Orofino, G. Carli, T. Urbano, A. Lucchesi, M. Brunoventre, M. Bonifacio, G. Binotto, F. Cavazzini, P. Ranalli, A. Allegra, B. Anaclerico, S. Mazzotta, F. Gherlinzoni, M. Tiribelli, C. Castiglioni, M. Landoni, D. Valsecchi, M. Magnoli, F. Passamonti, F. Palandri
POIESIS: a phase III study of add-on navtemadlin in JAK inhibitor-naïve myelofibrosis patients with a suboptimal response to ruxolitinib
2026 P. Vachhani, A. Yacoub, R. Rampal, T. Bradley, C. Harrison, T. Jain, A. Kuykendall, F. Palandri, J. Mascarenhas, H. Al-Ali, F. Passamonti, W. Rothbaum, S. Verstovsek, F.H. Heidel
Thrombophilia screening in patients with autoimmune hemolytic anemia: a single-center analysis
2026 B. Fattizzo, M. Abbatista, N. Cecchi, C. Novembrino, M. Boscolo-Anzoletti, G.L. Pedone, M. Bortolotti, A. Artoni, J.A. Giannotta, F. Peyvandi, F. Passamonti, W. Barcellini, M. Capecchi
Mixed Type Autoimmune Hemolytic Anemia: Clinical Severity and Treatment Patterns in a Large Observational Study
2026 F. Versino, U. Markovic, G.L. Pedone, S. Pergolizzi, F. Passamonti, W. Barcellini, A. Romano, B. Fattizzo
Preliminary Safety and Efficacy of Navitoclax Plus Ruxolitinib in Janus Kinase Inhibitor‐Naïve Patients With Myelofibrosis From the Multicenter, Open‐Label, Phase 2 Study (REFINE)
2026 F. Passamonti, J.M. Foran, A. Tandra, V. De Stefano, M.L. Fox, A. Mattour, M.F. Mcmullin, A.C. Perkins, G. Rodriguez‐macías, H.A. Sibai, A.R. Polepally, Y. Sun, A.S. Chopra, J.G. Harb, Q. Qin, J. Potluri, J. How
Characterization of a Newly Discovered Non‐Coding Variant in the EPO Gene Identified in Two Unrelated Italian Pedigrees With Erythrocytosis
2026 B. Mora, V. Bellani, D. Pietra, E. Tagliaferri, D. Cattaneo, O. Borsani, A. Iurlo, E. Fermo, P. Bianchi, E. Rumi, F. Passamonti
Adding transcriptomic features to MF prognostic models
2026 F. Passamonti
Aberrant single-cell phenotype and clinical implications of genotypically defined polyclonal plasma cells in myeloma
2025 M.C. Da Viá, F. Lazzaroni, A. Matera, A. Marella, A. Maeda, C. De Magistris, L. Pettine, A.G. Solimando, V. Desantis, G.M. Peretti, L. Mangiavini, R. Giorgino, S. Fabris, S. Pioggia, A. Marchetti, M. Barbieri, S. Lonati, A. Cattaneo, M. Tornese, M. Scopetti, E. Calvi, N. Latifinavid, G. Castellano, F. Torricelli, A. Neri, C. Fokkema, T. Cupedo, M. Lionetti, F. Passamonti, N. Bolli
In silico-identified putative inhibitors of paraspeckle assembly induce cell death by apoptosis in Multiple Myeloma cells and lead to the activation of the cGAS/STING pathway.
2025 V. Traini, D. Ronchetti, G. Fabbiano, I. Silvestris, N. Puccio, F. Torricelli, V. Manicardi, M. Barbieri, F. Colombo, L. Porretti, Y. Torrente, I. Eberini, F. Passamonti, N. Bolli, A. Neri, E. Taiana
The biological relevance of upregulated NONO protein in multiple myeloma through the regulation of cell cycle progression and drug treatment response
2025 G. Fabbiano, V. Traini, I. Silvestris, D. Ronchetti, M. Barbieri, F. Lazzaroni, M. Scopetti, A. Matera, A. Maeda, F. Colombo, L. Porretti, F. Passamonti, N. Bolli, E. Taiana
Treatment persistence and overall survival in myelofibrosis treated with ruxolitinib were not affected by the covid-19 pandemic, despite the reduced starting dose: Analysis of AIFA registries
2025 M. Breccia, S. Celant, F. Palandri, F. Passamonti, P.P. Olimpieri, V. Summa, A. Guarcello, G.A. Palumbo, F. Pane, P. Guglielmelli, P. Zinzani, P. Corradini, P. Russo
Severe aplastic anemia secondary to immune checkpoint inhibitor: case report and literature review
2025 A. Bosi, M.C. Di Chio, M. Bortolotti, G.A. Croci, F. Passamonti, W. Barcellini, B. Fattizzo
Exploring the role of NONO in transcriptional regulation of cellular pathways in Multiple Myeloma: insights into its paraspeckle-dependent and independent regulatory mechanisms
2025 E. Taiana, A. Devecchi, I. Silvestris, V. Traini, G. Fabbiano, M. Lionetti, M.C. Da Vià, N. Puccio, I. Craparotta, M. Bolis, R. Piva, A. Neri, L. Agnelli, F. Passamonti, N. Bolli, D. Ronchetti